West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
West Pharma (WST) Tops Q2 EPS by 17c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
July 25, 2019 6:08 AM EDTWest Pharma (NYSE: WST) reported Q2 EPS of $0.89, $0.17 better than the analyst estimate of $0.72. Revenue for the quarter came in at $469.7 million versus the consensus estimate of $460.4 million.
Net sales of $469.7 million grew 4.9%, organic sales growth was 8.1%; sales from a recent acquisition contributed an additional 20 basis points of growth.Reported-diluted EPS of $0.88 increased 17%.Adjusted-diluted EPS of $0.89 increased 27%.Company is raising full-year 2019 net sales guidance to a new range of between $1.810 billion and $1.825 billion.Company is raising full-year 2019 adjusted-diluted EPS guidance to a... More